SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0000
+0.0080 (+0.81%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.9920
Open0.9800
Bid0.98 x 1000
Ask1.00 x 800
Day's Range0.9660 - 1.0200
52 Week Range0.9100 - 3.7000
Volume32,833
Avg. Volume207,763
Market Cap17.683M
Beta (3Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Trade prices are not sourced from all markets
  • Benzingayesterday

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • PR Newswireyesterday

    Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Dec. 11, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.  As a result, the Company anticipates being able to transfer this credit and receive approximately $611,000 in net proceeds by year end. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss (NOL) Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey.

  • PR Newswire7 days ago

    Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology

    PRINCETON, N.J., Dec. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a review article discussing the therapeutic applications of its innate immune modulator technology, including dusquetide (the active ingredient in SGX942), its lead clinical Innate Defense Regulator (IDR).  The article entitled, "Targeting Innate Immunity to Treat Disease: Potential Therapeutic Applications", is published in the journal Drug Target Review online and is available here. Innate immune modulation as a therapeutic intervention reflects our enhanced understanding of an ancient aspect of the immune system.  With our increasingly sophisticated exploration of innate immunity, it has become possible to manipulate this system in a beneficial manner, potentially benefiting a wide range of patient populations, including oncology, oncology supportive care, infectious disease and acute and chronic inflammatory conditions.  These applications have been made possible by recent studies identifying the intricacies of the signaling pathways, and the ability to differentially impact these pathways.  Dusquetide is one of the first therapeutic approaches in this field, and is initially being developed in the context of oncology supportive care.  Preclinical data with dusquetide has demonstrated a wide range of potential application, including in gastrointestinal inflammation, infectious disease and oncology, discussed in the presentation here.  This brief review explores some of these concepts and proposes that innate immune modulation may become as important as other adaptive immune approaches (e.g., checkpoint inhibitors, CAR-T therapies) in the future.

  • Zacks Small Cap Research23 days ago

    SNGX: Two Phase 3 Data Readouts Over Next 12-15 Months…

    Revenues were comprised of non-dilutive government grants and contracts in support of RiVax®, SGX301, and SGX942 as well as a subaward from the Ebola collaboration with the University of Hawaii. The increase was mainly due to increased costs associated with the ongoing Phase 3 clinical trials. As of September 30, 2018, Soligenix had cash and cash equivalents of $11.7 million, due in part to a registered direct offering in July 2018 that raised net proceeds of $8.4 million.

  • GlobeNewswire28 days ago

    Investor Expectations to Drive Momentum within GEE Group, GigaMedia, China XD Plastics Company, Soligenix, Energy Transfer LP, and Oil-Dri Corporation Of America — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswirelast month

    Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland

    PRINCETON, N.J., Nov. 12, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.  The presentation will be given at the upcoming Fourth International Conference on Vaccines Research & Development on November 13-15, 2018 to be held at the Radisson Hotel Baltimore Downtown-Inner Harbor, MD.

  • PR Newswirelast month

    Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results

    PRINCETON, N.J., Nov. 9, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "Our primary focus remains the quality execution of our two pivotal Phase 3 clinical programs.  Following the positive recommendation recently received from the independent Data Monitoring Committee (DMC), we continue to enroll patients in our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin).

  • Zacks Small Cap Research2 months ago

    SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success…

    On October 15, 2018, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC), which conducted an unblinded analysis of the company’s ongoing Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial. The trial is testing the company’s lead product, SGX301, as a treatment for cutaneous T cell lymphoma (CTCL). The DMC recommended that the company enroll an additional 40 subjects into the trial to maintain 90% statistical power for the primary endpoint.

  • Zacks Small Cap Research2 months ago

    SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301

    To clear up any confusion regarding the DMC’s recommendation and what it means for the study we spoke with Dr. Richard Straube, Soligenix’s Chief Medical Officer, and asked him a few questions regarding the outcome of the interim analysis. David Bautz: Some investors may be surprised by the required addition of 40 patients to the study. Dr. Straube: First, we want to make it clear that nothing is wrong with the study and we weren’t far off with our estimated enrollment of approximately 120 patients.

  • PR Newswire2 months ago

    Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma

    PRINCETON, N.J. , Oct. 15, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • Benzinga2 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • PR Newswire2 months ago

    Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit

    PRINCETON, N.J., Oct. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been invited to present results from two of its development programs at National Organization for Rare Disorders' (NORD's) Rare Diseases and Orphan Products Breakthrough Summit on October 15-16, 2018 in Washington, DC. The presented results will be available for viewing throughout the conference and will address efficacy findings in two programs that have previously been granted orphan drug or fast track designation by the U.S. Food and Drug Administration (FDA).

  • Zacks Small Cap Research3 months ago

    SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?

    Soligenix (SNGX) is a late-stage biopharmaceutical company with two Phase III candidates. While we are waiting for the interim analysis of SGX301 in the coming month, we recently interviewed Dr. Richard C. Straube, Sr. VP & Chief Medical Officer of Soligenix (SNGX) with respect to the prospect of this late stage candidate. Following are the summary of what we get from Dr. Richard Straube.

  • PR Newswire3 months ago

    NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program

    PRINCETON, N.J. , Sept. 13, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

  • PR Newswire3 months ago

    Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry

    PRINCETON, N.J., Sept. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 25th Annual NewsMakers in the Biotech Industry on Friday, September 7 at 11:30AM ET.

  • PR Newswire3 months ago

    Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine

    PRINCETON, N.J., Sept. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of extended stability studies for RiVax® showing up to 100% protection in mice even after 12 months storage at 40 degrees Celsius (104 degrees Fahrenheit), as well as the identification of a potential in vitro stability indicating assay, critical to adequately confirming long-term shelf-life of the vaccine.  The article, entitled "Thermal Stability and Epitope Integrity of a Lyophilized Ricin Toxin Subunit Vaccine", is published in the journal Vaccine online and is available here.

  • PR Newswire3 months ago

    Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

    PRINCETON, N.J., Aug. 29, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease in a poster session at the upcoming European Society of Clinical Microbiology and Infectious Diseases / American Society of Microbiology Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance on September 4 - 7, 2018 to be held in Lisbon, Portugal.

  • PR Newswire4 months ago

    Soligenix Receives US Patent for Improved Production of Synthetic Hypericin

    Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Aug. 22, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • PR Newswire4 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • PR Newswire4 months ago

    Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results

    PRINCETON, N.J., Aug. 8, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the second quarter ended June 30, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "Our primary focus remains the quality execution of our two pivotal Phase 3 clincial programs.  We are continuing to enroll patients in our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin), where we anticipate the interim analysis in the October 2018 timeframe and final topline results in the first half of 2019.

  • PR Newswire5 months ago

    Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada

    PRINCETON, N.J., July 26, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing potential immune correlates of protection to facilitate vaccine approval under the Food and Drug Administration (FDA) Animal Rule. The presentation will be given at the upcoming 31st Annual Congress on Vaccines, Clinical Trials & B2B Conference on July 27-28, 2018 to be held at the Executive Airport Plaza Hotel & Conference Centre, Richmond, BC, Canada.

  • PR Newswire5 months ago

    Soligenix Announces Appointment of Mark Pearson to its Board of Directors

    PRINCETON, N.J. , July 24, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • PR Newswire5 months ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.

  • PR Newswire5 months ago

    Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation

    PRINCETON, N.J., July 9, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of allowance for European (application No. 12786638.2) and Canadian (application No. 2836273) patent applications further extending protection around ThermoVax® including coverage of the Company's ricin toxin vaccine, RiVax®. The issued patent is complementary to previous patents, including US patents 8,444,991 granted on May 21, 2013 and 8,808,710 granted on August 19, 2014, that include claims for methods of making stabilized vaccines and their attendant compositions.  In this new patent, the main claims cover formulations of Soligenix's proprietary thermostabilized ricin toxin vaccine, RiVax®.  The thermostable formulation of RiVax® has been shown to be stable for at least 12 months at temperatures up to 40 degrees Celsius (104 degrees Fahrenheit) and to provide 100% protection to non-human primates exposed to aerosol ricin challenge in preclinical studies.

  • Zacks Small Cap Research5 months ago

    SNGX: New Financing Boosts Balance Sheet

    In early July, Soligenix (SNGX) closed an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix from this offering were approximately $8 million.